Action on fibrinolysis and platelet aggregation of a synthetic, heparin-like sulfated polyanion (SP 54) given orally and parenterally, as related to lipidic fractions. Trials on long-term prophylactic treatment under double-blind conditions.
D000284:Administration, Oral; D001796:Blood Protein Disorders / Q000188:drug therapy; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008071:Lipoprotein Lipase / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D010919:Placebos; D010973:Platelet Adhesiveness / Q000187:drug effects*; D011134:Polysaccharides / Q000008:administration & dosage / Q000627:therapeutic use*; D013464:Sulfuric Acids / Q000008:administration & dosage / Q000627:therapeutic use; D013916:Thrombelastography; D013927:Thrombosis / Q000188:drug therapy; D014280:Triglycerides / Q000097:blood
D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D010919:Placebos; D011134:Polysaccharides; D013464:Sulfuric Acids; D014280:Triglycerides; D002784:Cholesterol; D008071:Lipoprotein Lipase